A retrospective cohort study evaluating characteristics and treatment patterns of new users of fluticasone furoate/vilanterol post approval period in United Kingdom
Latest Information Update: 04 Jul 2023
Price :
$35 *
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 21 Sep 2018 New trial record
- 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management